Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia

8 Feb 2018

Abstract excerpt

Abstract In acute myeloid leukemia (AML), chemotherapy resistance remains prevalent and poorly understood. Using functional proteomics of patient AML specimens, we identified MEF2C S222 phosphorylation as a specific marker of primary chemoresistance. We found that Mef2cS222A/S222A knock-in mutant mice engineered to block MEF2C phosphorylation exhibited normal hematopoiesis, but were resistant to leukemogenesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29431698
DOI: 10.1158/2159-8290.cd-17-1271

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid LeukemiaPMID 29431698Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read ↗

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsSemantic proximity Read ↗

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patientsSemantic proximity Read ↗

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.Semantic proximity Read ↗

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.Semantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLSemantic proximity Read ↗

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib ResistanceSemantic proximity Read ↗

Early response evaluation by single cell signaling profiling in acute myeloid leukemiaSemantic proximity Read ↗

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read ↗

CKS1-dependent proteostatic regulation has dual roles combating acute myeloid leukemia whilst protecting normal hematopoiesisSemantic proximity Read ↗

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLSemantic proximity Read ↗

ACSL4-Associated Lipid Metabolism is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.